Last reviewed · How we verify
Bendamustine plus Rituximab
Bendamustine chemotherapy damages cancer cell DNA while rituximab targets CD20 on B cells to enhance immune destruction of lymphoma cells.
Bendamustine chemotherapy damages cancer cell DNA while rituximab targets CD20 on B cells to enhance immune destruction of lymphoma cells. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | Bendamustine plus Rituximab |
|---|---|
| Sponsor | University of Giessen |
| Drug class | Alkylating agent + monoclonal antibody combination |
| Target | DNA (bendamustine); CD20 (rituximab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bendamustine is an alkylating agent that cross-links DNA and induces apoptosis in rapidly dividing cells. Rituximab is a chimeric monoclonal antibody against CD20, a surface antigen on B cells, which mediates antibody-dependent cellular cytotoxicity and direct cell death. The combination leverages chemotherapy cytotoxicity with targeted immunotherapy to improve efficacy in B-cell malignancies.
Approved indications
- B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Fatigue
- Infection
- Infusion reactions
- Anemia
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
- CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma (PHASE1)
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bendamustine plus Rituximab CI brief — competitive landscape report
- Bendamustine plus Rituximab updates RSS · CI watch RSS
- University of Giessen portfolio CI